Welcome, Guest. Please login or register.
May 20, 2024, 11:57:08 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 87
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 80
Total: 80


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Treatment Decision  (Read 10055 times)

0 Members and 1 Guest are viewing this topic.

Offline Ginabros

  • Member
  • Posts: 28
Treatment Decision
« on: March 21, 2017, 04:25:52 pm »
Hi everyone!

I have had both Hep B and C for over 30 years. I am on the antiviral, called Entecavir, to keep my Hep B viral load undetectable. Due to my being co-infected with both viruses I have been hesitant to try any of the new Hep C treatments. However, when I finally decided to give Harvoni a try this warning came out: https://www.fda.gov/Drugs/DrugSafety/ucm522932.htm. I called Gilead but I have been unsuccessful in finding out of whether the population of people who had their Hep B virus reactivated fall within the “was fully cured and seroconverted” group or my category : “still have the Hep B virus but antiviral med keeps it dormant”. I am scared to gamble with my health and make my condition worse. My doctor says let’s try, but it is not his health that is on the line.  I couldn’t find any message board/forum for Hep B and C co-infected people or any studies on successful treatment outcomes so I would like to ask you for your opinion on the above dilemma I have.. What's your take on it?

And a few more questions..

Do you know how I can get in touch with someone from Gilead who can give me the additional info I need and not just read out loud what the label says?

My Hep C gynotype is 1. Is Harvoni the most effective and proven treatment on the market right now? What tests (HCV RNA, scans etc.) would be helpful in telling if I am a good candidate for it?

I read that some people who responded to Harvoni and SVR, physically  feel ever worse after the treatment. Is it common?

Thank you so much for taking your time to read this and provide your opinion!

Offline Lynn K

  • Global Moderator
  • Member
  • Posts: 4,544
  • Get tested, get treated, get cured, fight Hep c!
Re: Treatment Decision
« Reply #1 on: March 21, 2017, 05:43:09 pm »
There is also another new medicine called Epclusa from Giliead with an even higher likelihood of cure at 98% for genotype 1a unfortunately it has the same box warning. Although Harvoni is one of the best it is not the only treatment available.

Here is a link about Harvoni which includes contact information.


Here is a link to the Harvoni prescribing information sheet.


And the box warning information about Hep B from the above document


Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with HARVONI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1)]."

Yeah you are definitely in a catch 22 situation you don't want to awaken the virus but it is not a good thing to be infected with both hep b and hep c it would be great to eliminate one of them. I hope you are seeing a hepatologist as your situation is a bit more complicated that most. I do note the warning references those with hep b who are NOT receiving anti hep b medicines and you are.

As far as sides there have been sadly a few here who experienced difficult symptoms which they attribute to their treatment but as far as I am aware there has not been a link established between their symptoms and their treatment.

Fortunately, the majority of people had little to no side effects on treatment with either Harvoni or Epclusa mostly just a few mild headaches or some tiredness while some experiences an increase in energy. The headaches are best addressed by ensuring you are drinking adequate fluids the old 8 glasses a day we are all recommended to drink any way or maybe just a bit more.

I wouldn't really dwell on the remote possibility of troublesome side effects I would be more thinking about the hep b concern. There are also other medicines that can treat hep c so I am really thinking you should see a hepatologist or at least a gastroenterolgist experienced in treating both hep b and hep c they will be best able to answer the question which treatment will be most safe and effective for you.

Good luck

« Last Edit: March 21, 2017, 05:50:18 pm by Lynn K »
Genotype 1a
1978 contracted, 1990 Dx
1995 Intron A failed
2001 Interferon Riba null response
2003 Pegintron Riba trial med null response
2008 F4 Cirrhosis Bx
2014 12 week Sov/Oly relapse
10/14 fibroscan 27 PLT 96
2014 24 weeks Harvoni 15 weeks Riba
5/4/15 EOT not detected, ALT 21, AST 20
4 week post not detected, ALT 26, AST 28
12 week post NOT DETECTED (07/27/15)
ALT 29, AST 27 PLT 92
24 week post NOT DETECTED! (10/19/15)
44 weeks (3/11/16)  fibroscan 33, PLT 111, HCV NOT DETECTED!

Offline elias

  • Member
  • Posts: 285
Re: Treatment Decision
« Reply #2 on: March 21, 2017, 06:34:58 pm »
Hi Ginabros:

I dont know enough bout HBV/HCV co-infection to directly address your concern.

But the following  CME Internet Symposium discussion does address this based on the most recent information from the annual AASLD Liver Meeting. It's a fairly long podcast, over 40 minutes. The discussion of HCV treatment reactivating HBV infection is in the latter part of the symposium. Its discussed by Nezam Afdal , one of the nation's top medical specialists in the field of HCV treatment:


Hope it helps you put this in perspective.


I agree with Lynn here bout Epclusa being more effective even for GT 1.

The best summary of Gilead's research on this is in the following New England J. of Medicine article. Astral I Phase 3 study:


Treatment outcomes and side-effects described in detail

Contracted HCV ~age 12
Diagnosed: September 2016 GT2b
F3 by Fibrosure: 0.66
Necroinflammat activity: A3 0.76
VL Sep. 12, 2016: 1.44 million/ Log: 6.157
AST:71/ ALT:114   Sept. 1, 2016 Before treatment
4 week after beginning  Epclusa:
AST 17/ALT 11
Began Epclusa:  October 22, 2016
End of Treatment [EOT]: January 13. 2017
SVR 12 April14-HCV Not Detected

Offline Gaj

  • Member
  • Posts: 172
  • Optimist
Re: Treatment Decision
« Reply #3 on: March 21, 2017, 10:08:27 pm »
Hi Ginabros,

Please be aware that this issue of HBV reactivation or "flare" has only occurred in a very small percentage of HBV infected patients who have treated for HCV, it is only a risk in those who have not fully sero-converted. What often happens with dual infection is that the HCV virus tends to outcompete and suppress HBV. Once HCV treatment occurs the removal of the HCV virus can provide the HBV with the opportunity to become dominant and start replicating at increased levels again which causes the normal risks associated with active HBV.

The main points from Gilead's warning are:

HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy.

See the underlined section in Gilead's above advice. You are currently taking Entecavir which would considerably reduce the risk of reactivation occurring both during and after treatment.

Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated

From what you say you have a HBV viral load which is why you are prescribed Entecavir which can be used with most of the current HCV medications including Harvoni and Epclusa. As you have a co-infection it is very important that you discuss the most appropriate treatment (which should include a HBV suppressor such as Entecavir) with a specialist who has experience with both HIV and HBV and that you both ensure that appropriate monitoring of your HBV occurs during and after HCV treatment.

Best wishes for a successful treatment.
« Last Edit: March 21, 2017, 10:14:08 pm by Gaj »
Male - 61 years
Genotype 3a (since 1978?)
Diagnosed 2012
Treated 2013 PEG/Riba/Dac (Relapsed)
F4 - HCC#1 Resected 06/15 - #2 RFAblated 11/15
11/18/15 Commenced Generic Tx - Sof/Dac/Riba (24wks)
Pre Tx = ALT: 270  AST: 209  ALB: 31
05/05/16 = ALT: 34  AST: 32  ALB: 40  VL: Undetected (EOT)
06/16/16 = Relapsed
06/23/16 = ALT: 92  AST: 59  ALB: 40  VL: 290,770
01/12/17 3rd Tx - Zepatier + Sofosbuvir (16wks)
05/03/17 EOT und
06/22/17 SVR7 und
07/27/17 SVR12 UND!
10/26/17 SVR24 UND & Cured!!!

Offline I fightis thetitis

  • Member
  • Posts: 129
Re: Treatment Decision
« Reply #4 on: March 27, 2017, 06:45:52 am »
Hey Ginabros,

What are your recent labs like?
If you post them in your signature line that will help you if we hear from some hepc/b alum who have gone through this already.
What is the current with your liver?

Best of luck!

M59  56@start of TX. date infected:1976
diagnosed 1997 - asymtomatic
Genotype 1a
AST 111 -ALT 124 - AFP -89
Viral Load 1900000 - Log 6.28
Fibro Test F4 ActiTest A3
Harvoni 24 wks - start date 11/24/15

6 Week Labs VL Undetected!
104 weeks EOT Undetected.

8/25/17 Fibrosure score 80 = F4
11/10/17 Fibroscan 7.5 mean 1.6 m/s = F2
8/2018 Ultra sound normal.

Offline Ginabros

  • Member
  • Posts: 28
Re: Treatment Decision
« Reply #5 on: March 28, 2017, 09:20:07 pm »
Hi everyone!

Thank you so very much for your responses!
I have decided that I need a little more information about the condition of my liver at the moment , before I can make the treat or no treat decision. For the last few years the doc was only checking my HBV markers  and twice a year had me do ultrasound. He said that if I am not on treatment for HCV no need to draw blood for this since we already know I have the virus. My ALT has been between 50 and 70, sometimes slight elevated AST. HBV viral load is undetectable since I am on entecavir but i am not cured and still have the virus.  The last HCV viral load I did was a few years ago and it was pretty high. I am genotype 1 (don't remember the letter). I will post this data in the signature line soon.
So, I talked to my doc and the plan is to do labs for HCV and fibroscan. Then I will try to make the wise decision..... Having both viruses makes it more complicated and scary.
If you hear from anyone coinfected like me, I would really appreciate you letting me know so I can get in touch with that person. Or vise versa..

Again, thank you for your support!


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.